Enzyme Restores Function with Diabetic Kidney Disease

Mouse findings reverse prevailing theory; point to potential treatment options

Researchers at the University of California, San Diego School of Medicine say that, while a prevailing theory suggests elevated cellular levels of glucose ultimately result in diabetic kidney disease, the truth may, in fact, be quite the opposite. The findings could fundamentally change understanding of how diabetes-related diseases develop – and how they might be better treated. … Read the full story from the UC San Diego News Center


Kumar Sharma, MD, FAHA Kumar Sharma, MD, FAHA, senior author of the study report, is professor of medicine and director of the Center for Renal Translational Medicine in the Division of Nephrology-Hypertension.

Dr. Laura DuganFirst author Laura L. Dugan, MD, at right, is professor of neurosciences and professor and chief of the Division of Geriatrics in the Department of Medicine. She holds the Larry L. Hillblom Chair in Geriatric Medicine.

Second author Young-Hyun You is an associate project scientist in the Division of Nephrology-Hypertension,

Other DOM faculty coauthors are Sameh S. Ali, assistant professor of medicine in the Division of Geriatrics, and Robert K. Naviaux, MD, PhD, professor of medicine in the Division of Medical Genetics.

Citation for the study report:

Laura L. Dugan, Young-Hyun You, Sameh S. Ali, Maggie Diamond-Stanic, Satoshi Miyamoto, Anne-Emilie DeCleves, Aleksander Andreyev, Tammy Quach, San Ly, Grigory Shekhtman, William Nguyen, Andre Chepetan, Thuy P. Le, Lin Wang, Ming Xu, Kacie P. Paik, Agnes Fogo, Benoit Viollet, Anne Murphy, Frank Brosius, Robert K. Naviaux and Kumar Sharma. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123(11):4888–4899. doi:10.1172/JCI66218.  |  Full text (UCSD only)

Related UC San Diego news stories:

Urine Biomarkers Reveal Mitochondrial Dysfunction in Diabetic Kidney Disease

Researchers at the University of California, San Diego School of Medicine have identified 13 metabolites – small molecules produced by cellular metabolism – that are significantly different in patients with diabetes and chronic kidney disease compared to healthy controls. … Read the full story from the UC San Diego News Center


Kumar Sharma, MD, FAHA First author Kumar Sharma, MD, FAHA, is professor of medicine and director of the Center for Renal Translational Medicine in the Division of Nephrology-Hypertension.

Citation for the study report:

Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease. Kumar Sharma, Bethany Karl, Anna V. Mathew, Jon A. Gangoiti, Christina L. Wassel, Rintaro Saito, Minya Pu, Shoba Sharma, Young-Hyun You, Lin Wang, Maggie Diamond-Stanic, Maja T. Lindenmeyer, Carol Forsblom, Wei Wu, Joachim H. Ix, Trey Ideker, Jeffrey B. Kopp, Sanjay K. Nigam, Clemens D. Cohen, Per-Henrik Groop, Bruce A. Barshop, Loki Natarajan, William L. Nyhan, and Robert K. Naviaux JASN ASN.2013020126; published ahead of print October 10, 2013, doi:10.1681/ASN.2013020126  |  Full text (UCSD only)

Related UC San Diego news stories:

How Infectious Disease May Have Shaped Human Origins

Inactivation of two genes may have allowed escape from bacterial pathogens, researchers say

Roughly 100,000 years ago, human evolution reached a mysterious bottleneck: Our ancestors had been reduced to perhaps five to ten thousand individuals living in Africa. In time, “behaviorally modern” humans would emerge from this population, expanding dramatically in both number and range, and replacing all other co-existing evolutionary cousins, such as the Neanderthals. … Read the full story from the UCSD Newsroom

Roche Funds Drug Discovery Projects at UC San Diego

The new UC San Diego-Roche Extending Innovation Network (EIN) program has been launched with selection of its first three research projects at the University of California, San Diego School of Medicine. The UC San Diego-Roche EIN program, which was formalized in June 2011, aims to accelerate the discovery of new drug therapies through research innovation at the interface of industry and academia. The program is slated to grow in the coming years as additional rounds of proposals are solicited. … Read the full story from the UCSD Newsroom

M. Geoffrey Rosenfeld, MD
M. Geoffrey Rosenfeld, MD (pictured above), is a co-investigator with Xiang-Dong Fu, PhD, on one of the three UC San Diego-Roche EIN-funded projects, in which the investigators will use genomic and RNA-based approaches to identify new drug targets.

Dr. Rosenfeld is Professor of Medicine in the Division of Endocrinology and Metabolism and a professor of the Howard Hughes Medical Institute. Dr. Fu is Professor of Cellular and Molecular Medicine and a member of the Institute for Genomic Medicine.